OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2019

The Opioid-Induced Constipation (OIC) is a new and rapidly establishing market currently dominated by OTC laxatives set to undergo substantial growth between 2014 and 2019. The main drivers of growth will be an increase in the diagnosed OIC population. This is fuelled by a relaxation of regulations regarding opioid treatment, particularly in the chronic non-cancer pain population. As a result opioid use has risen sharply in the last 15 years. Concurrently, there has been a rapid increase in patients experiencing OIC, with approximately 40-50% of chronic opioid users reporting symptoms. Traditionally, constipation has been treated with laxatives based on empirical research. However, the efficacy of laxatives to treat OIC is relatively poor and only provides adequate relief for approximately 50% of patients. Prior to 2008, the OIC market was desolate, with no approved pharmaceutical (non-laxative) treatment for this condition. The products that have been approved in the past have come with heavy restrictions limiting their use for the majority of OIC sufferers. However, the OIC therapeutic market is set to enter an explosive period of growth over the five-year forecast period. This advance is catalyzed by a major shift in the OIC treatment algorithm with the entry of several highly- targeted, efficacious, orally-formulated drugs. The competitive landscape will continue to evolve over the forecast period.

Full Report Details at
- http://www.fastmr.com/prod/1124667_opportunityanalyzer.aspx?afid=301

Key Questions Answered

* The OIC market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the OIC market?
* The late-stage OIC pipeline is heavily congested with several drugs in the same class, PAMORAs. Will the late-stage drugs make a significant impact on the OIC market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
* The current OIC market is dominated by OTC laxatives. How will the advent of highly targeted orally-formulated prescription drugs change the drug treatment landscape for OIC? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?

Key Findings

* The main driver of the enormous expansion of the OIC market will be the dramatic increase in the number of reported OIC cases, which is attributable to the relaxation of opioid prescribing regulations.
* The second largest driver will be the launch of several highly anticipated, targeted, efficacious treatment options, with a congested and competitive late stage clinical pipeline.
* To gain approval it is essential for companies to demonstrate high efficacy while proving no reduction of analgesia or Major Cardiovascular Adverse Effects (MACE), by selecting appropriate clinical trial endpoints.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023
- OpportunityAnalyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021